Siegfried Holding AG · SIX:SFZN
Siegfried — FY2016 Earnings Presentation
18 slides from Siegfried's earnings presentation, Mar 14, 2017
Slide 1: Welcome to the Media + Analysts' Conference
Welcome to the Media + Analysts’ Conference Zurich, March 14, 2017
Slide 2: Important Notice
Important Notice This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you solely for your information and you may not reproduce it or redistribute to any other person. The contents of this document are to be kept strictly confidential b
Slide 3: Agenda
1. Highlights 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 3
Slide 4: Highlights
Highlights — Sharp increase in sales to CHF 717.7 million, 49.3% increase in CHF (+47.3% in LC) — EBITDA CHF 104.2 million (+30.1%) before and 96.7 million after integration costs — Net profit of CHF 27.9 million below prior year due to integration costs, higher financing costs and tax expense vs. t
Slide 5: Facts & Figures
1. Highlights 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 5
Slide 6: Net sales
Net sales CHF million 2016 2015 Change CHF (LC) Drug Substances 557.9 333.2 +67.5% (+65.4%) Drug Products 159.8 147.4 +8.4% (+6.3%) Total 717.7 480.6 +49.3% (+47.3%) Comments — Organic sales growth with 6.7% above market — Drug Substance growth driven by acquisition effect of former BASF business. —
Slide 7: Significant increase in operating profits
Significant increase in operating profits In Mio. CHF 120.0 109.2 104.2 100.0 90.7 80.1 80.0 60.0 54.2 46.4 40.0 34.1 33.4 20.0 0.0 Gross profit EBITDA EBIT Net profit 2015 2016 — Non-recurring integration costs were CHF 7.5m on EBITDA and EBIT level (2015 CHF 3.0m) — This leads to the reported EBIT
Slide 8: Dilution of operating margins due to acquisition
Dilution of operating margins due to acquisition In % 20.0% 18.9% 16.7% 15.2% 14.5% 15.0% 9.7% 10.0% 7.6% 7.1% 4.6% 5.0% 0.0% Gross profit margin EBITDA margin EBIT margin Net profit margin 2015 2016 — Dilutive effect from acquisition on operating margins (BASF API and supply business) — Negative im
Slide 9: P&L
P&L CHF million 2016 2015 Net sales 717 729 480 571 Cost of goods sold – 608 509 – 389 919 Gross profit 109 220 90 652 Marketing and sales costs – 16 028 – 13 041 Research and development costs – 21 193 ** – 23 289 Admin and general overhead costs – 31 488 – 23 311 Other operating income 6 239 12 42
Slide 10: Significant improvement of operating cash flow
Significant improvement of operating cash flow CHF million 2016 2015 Operating Cashflow before changes in NWC 95 907 65 025 Change in NWC –38 794 –41 950 Operating Cashflow 57 113 23 075 Purchase of PPE and intangibles (net) – 68 287 – 89 370 Acquisitions 2 157 – 160 361 Other investing activities 3
Slide 11: Pay-out – proposal to the AGM on April 20, 2017
Pay-out – proposal to the AGM on April 20, 2017 — The Board of Directors proposes a pay-out from the capital contribution reserves of CHF 2.00 per share (2016: CHF 1.80 per share) to the AGM on April 20, 2017 (in total appr. CHF 8.0m). — Pay-out from capital contribution reserve, tax free. — Remaini
Slide 12: Status and Strategy
1. Highlights 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 12
Slide 13: Siegfried's new production network offers unique flexibility and integration
Siegfried`s new production network offers an unique combination of flexibility and integration on a global base Media + Analysts’ Meeting 2017 March 14, 2017 13
Slide 14: New offers at record level
New offers at record level Sales potential new projects* Year acquired 2014 2015 2016 0 50 100 150 200 250 Mio CHF *For 5 years (2017-2021). = after risk adjustment Media + Analysts’ Meeting 2017 March 14, 2017 14
Slide 15: EVOLVE strategy for 2016–2020
Siegfried’s EVOLVE strategy for 2016–2020: Siegfried will further enhance its pure-play CDMO business model Fields of action Strengthen offerings: – Expand global solida drug product footprint – Expand overall presence with own production facilities (e.g. US) – Enhance development setup Growth G
Slide 16: Outlook
1. Highlights HY 2016 2. Facts & Figures 3. Status and Strategy 4. Outlook Media + Analysts’ Meeting 2017 March 14, 2017 16
Slide 17: Outlook
Outlook The Siegfried Group expects − high single-digit sales growth − Double-digit growth of EBITDA − improved EBITDA margin Media + Analysts’ Meeting 2017 March 14, 2017 17
Slide 18: Thank you for your attention
Siegfried expect more Thank you for your attention